Canadian Biotech Immune Biosolutions said it has initiated a Phase 1 clinical trial of its IBIO123 inhaled antibody therapy, which it is developing for the treatment of COVID-19. According to the company, the trial is being conducted in South Africa and will evaluate IBIO123 versus placebo in patients with symptomatic COVID-19.
Earlier this year, the Canadian government’s Strategic Innovation Fund granted Immune Biosolutions $13.4 million that the company is using for development of antibody therapies for COVID-19 through Phase 2 and to increase manufacturing capacity.
Immune Biosolutions Chief Corporate Development Officer Luc Paquet commented, “We believe that IBIO123 is a potentially ideal candidate to treat symptomatic patients in the acute phase and possibly prevent long-term complications from the infection. We are excited to eventually allow the population as a whole to benefit from it.”
Chief Medical Officer Bruno Maranda said, “This clinical trial is an important step toward potentially providing promising new treatments for patients with mild to severe COVID-19 symptoms. IBIO123 would provide broad coverage of the current variants of concern through multiple synergistic modes of action and simple inhalation administration.”
Read the Immune Biosolutions press release.
